Biohit Oyj is a Finnish biotechnology company operating on global markets. Our mission, “Innovating for Health”, describes our innovative products and services, which aim to promote medical research and early diagnosis, and prevent serious illnesses.
Our goal is to improve peoples quality of life by preventing diseases, human suffering and financial loss. Biohit is headquartered in Helsinki and has subsidiaries located in Italy and the United Kingdom. Biohits Series B shares (BIOBV) are listed in Nasdaq OMX Helsinki Small Cap group and in the healthcare sub-sector. More information about the share and financials is available in the Investors section of this site.
Biohit serves healthcare organisations and patients by promoting gastric and colorectal health. The most recent innovation is Acetium®, which promotes smoking cessation.
Cost-effective innovations for healthcare
Gastrointestinal diseases are a growing world-wide concern, with related medical, ethical and financial problems. World-wide, gastrointestinal diseases are the most common cause for people to seek treatment or suffer problems due to a lack of treatment. As the population ages, the need for healthcare will increase further, leading to an urgent requirement for new, cost-effective solutions.
The numerous health-related problems caused by smoking are the most common preventable form of mortality in western countries. Biohit helps people to give up smoking with a new method that does not cause nicotine addiction. The Acetium® lozenge is a natural preparation containing L cysteine which has already helped numerous smokers to stop smoking altogether or significantly reduce their smoking.
Biohit continuously develops its products and services to address societys needs. Our products and services are researched, cost-effective innovations for diagnosing and preventing diseases and associated risks.
Innovations and patents
Biohits operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.